FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

MLA

Malka, David, et al. “FOLFOX Alone or Combined with Rilotumumab or Panitumumab as First-Line Treatment for Patients with Advanced Gastroesophageal Adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): A Randomised, Open-Label, Three-Arm Phase II Trial.” European Journal of Cancer (Oxford, England : 1990), vol. 115, July 2019, pp. 97–106. EBSCOhost, https://doi.org/10.1016/j.ejca.2019.04.020.

APA

Malka, D., François, E., Penault-Llorca, F., Castan, F., Bouché, O., Bennouna, J., Ghiringhelli, F., de la Fouchardière, C., Borg, C., Samalin, E., Bachet, J.-B., Raoul, J.-L., Miglianico, L., Bengrine-Lefèvre, L., Dahan, L., Lecaille, C., Aparicio, T., Stanbury, T., Perrier, H., … Taïeb, J. (2019). FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. European Journal of Cancer (Oxford, England : 1990), 115, 97–106. https://doi.org/10.1016/j.ejca.2019.04.020

Chicago

Malka, David, Eric François, Frédérique Penault-Llorca, Florence Castan, Olivier Bouché, Jaafar Bennouna, François Ghiringhelli, et al. 2019. “FOLFOX Alone or Combined with Rilotumumab or Panitumumab as First-Line Treatment for Patients with Advanced Gastroesophageal Adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): A Randomised, Open-Label, Three-Arm Phase II Trial.” European Journal of Cancer (Oxford, England : 1990) 115 (July): 97–106. doi:10.1016/j.ejca.2019.04.020.